To our knowledge, this is the first study to examine the effect of GLP-1 RA use on RA disease activity and cardiovascular risk profile in patients with RA and overweight or obesity, the researchers wrote
GLP-1 drugs, such as semaglutide (sold under brand names like Ozempic and Wegovy), act by mimicking hormones that help regulate appetite and blood sugar
It is a comprehensive program designed to remove the financial stress often associated with GLP-1 weight loss treatments
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity